---

Mesenchymal Stem/Stromal Cells for Treatment of Rheumatoid Arthritis

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Ashim Gupta*, Manish Khanna

Volume : 8, Issue : 2, Year : 2022

Article Page : 47-53

https://doi.org/10.18231/j.ijor.2022.012

Suggest article by email

Get Permission

Abstract

Rheumatoid Arthritis (RA) is a chronic, inflammatory, autoimmune disorder involving joint pathogenesis, cartilage and bone deformities, along with systemic comorbidities, affecting over 75 million people worldwide. At present there is no cure for RA and the current treatment modalities utilized have limitations and side effects. Over the last decades, mesenchymal stem/stromal cells (MSCs), both autologous and allogenic, have emerged as potential safe and effective alternatives. In this review, we highlighted the safety and efficacy of both autologous as well as allogenic MSCs to treat RA based on recently published clinical studies. These studies demonstrated that use of autologous or allogenic MSCs is safe and laid the foundation for multi-center prospective open label non-randomized trials and double blinded randomized controlled trials with larger sample size to further establish the safety and efficacy of these MSCs to alleviate symptoms of RA, thereby, ultimately justifying their clinical use.
 

Keywords: Rheumatoid arthritis, Mesenchymal stem cells, Mesenchymal stromal cells, MSCs, Bone marrow­derived MSCs, Adipose­derived MSCs, Umbilical Cord­derived MSCs, Umbilical cord blood­derived MSCs, clinical trials

How to cite : Gupta A, Khanna M, Mesenchymal Stem/Stromal Cells for Treatment of Rheumatoid Arthritis. IP Int J Orthop Rheumatol 2022;8(2):47-53

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.